|
[1] EBATA T,ERCOLANI G,ALVARO D,et al. Current status on cholangiocarcinoma and gallbladder cancer[J]. Liver Cancer,2016,6(1):59-65.
|
|
[2] FRANKLIN C,LIVINGSTONE E,ROESCH A,et al. Immunotherapy in melanoma:Recent advances and future directions[J]. Eur J Surg Oncol,2017,43(3):604-611.
|
|
[3] BEDKE J,STHLER V,STENZL A,et al. Immunotherapy for kidney cancer:Status quo and the future[J]. Curr Opin Urol,2018,28(1):8-14.
|
|
[4] JIN TQ,XU F,DAI CL. Research advances in immunotherapy for liver metastasis of pancreatic cancer[J]. J Clin Hepatol,2018,34(11):2469-2474.(in Chinese)金添强，徐锋，戴朝六．胰腺癌肝转移免疫治疗的研究进展[J]．临床肝胆病杂志，2018,34(11):2469-2474.
|
|
[5] MENG QH,TIAN J,QIN FZ,et al. Research progress of PD-1/PD-L1 pathway inhibitor in the immunotherapy of digestive system neoplasm[J]. Chin J Clin Pharmacol Ther,2018,23(8):942-948.(in Chinese)蒙秋华，田婧，覃斐章，等．PD-1/PD-L1通路抑制剂在消化系统肿瘤免疫治疗的研究进展[J]．中国临床药理学与治疗学，2018,23(8):942-948.
|
|
[6] GANI F,NAGARAJAN N,KIM Y,et al. Program death 1 immune checkpoint and tumor microenvironment:Implications for patients with intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol,2016,23(8):2610-2617.
|
|
[7] YU F,GONG L,MO Z,et al. Programmed death ligand-1,tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients:Possible immunotherapy implications[J]. Biosci Trends,2019,13(1):58-69.
|
|
[8] SABBATINO F,VILLANI V,YEARLEY JH,et al. PD-L1 and HLA Class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma[J]. Clin Cancer Res,2016,22(2):470-478.
|
|
[9] BANG YJ,DOI T,BRAUD FD,et al. Safety and efficacy of pembrolizumab(MK-3475)in patients(pts)with advanced biliary tract cancer:Interim results of KEYNOTE-028[J]. Eur J Cancer,2015,51(3):s112.
|
|
[10] SUI M,LI Y,WANG H,et al. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1blockade[J]. J Immunother Cancer,2019,7(1):125.
|
|
[11] ASAOKA Y,IJICHI H,KOIKE K. PD-1 Blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med,2015,373(20):1979.
|
|
[12] MOU H,YU L,LIAO Q,et al. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1expression:A case report[J]. BMC Cancer,2018,18(1):1105.
|
|
[13] PYO JS,KANG G,KIM JY. Prognostic role of PD-L1 in malignant solid tumors:A meta-analysis[J]. Int J Biol Markers,2017,32(1):e68-e74.
|
|
[14] LIU RC,CONSUEGRA G,CHOU S,et al. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers[J]. Clin Exp Dermatol,2019,44(6):643-646.
|
|
[15] ZHAO R,CHINAI JM,BUHL S,et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function[J]. Proc Natl Acad Sci U S A,2013,110(24):9879-9884.
|
|
[16] JING CY,FU YP,YI Y,et al. HHLA2 in intrahepatic cholangiocarcinoma:An immune checkpoint with prognostic significance and wider expression compared with PD-L1[J]. J Immunother Cancer,2019,7(1):77.
|
|
[17] GARNELO M,TAN A,HER Z,et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma[J]. Gut,2017,66(2):342-351.
|
|
[18] GOEPPERT B,FRAUENSCHUH L,ZUCKNICK M,et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer[J]. Br J Cancer,2013,109(10):2665-2674.
|
|
[19] TRAN E,TURCOTTE S,GROS A,et al. Cancer immunotherapy based on mutation-specific CD4+T cells in a patient with epithelial cancer[J]. Science,2014,344(6184):641-645.
|
|
[20] KAN N,YOSHIKAWA K,MATSUSHITA N,et al. The case of a patient with peritoneal metastasis from cholangiocarcinoma who responded to adoptive immunotherapy and cetuximab[J]. Gan To Kagaku Ryoho,2013,40(12):1759-1761.
|
|
[21] SHIMIZU K,KOTERA Y,ARUGA A,et al. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma[J]. J Hepatobiliary Pancreat Sci,2012,19(2):171-178.
|
|
[22] JIN K. DC-CIK cells immunotherapy study on the immune function of patients with bile duct carcinoma after surgery[D].Suzhou:Soochow University,2013.(in Chinese)金奎．DC-CIK细胞免疫治疗对胆管癌术后患者免疫功能影响的研究[D]．苏州:苏州大学，2013.
|
|
[23] LEPISTO AJ,MOSER AJ,ZEH H,et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors[J]. Cancer Ther,2008,6(B):955-964.
|
|
[24] KOBAYASHI M,SAKABE T,ABE H,et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer[J]. J Gastrointest Surg,2013,17(9):1609-1617.
|
|
[25] KOIDO S,KAN S,YOSHIDA K,et al. Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy[J].Anticancer Res,2014,34(11):6353-6361.
|
|
[26] LIN Z,XIE QL,LI SY,et al. Advanced of HER-2/neu epitope anti-tumor vaccine[J]. Chin J Clin Pharmacol Ther,2019,24(9):1046-1052.(in Chinese)林忠，谢群莉，李胜英，等．HER-2/neu表位肿瘤疫苗研究进展[J]．中国临床药理学与治疗学，2019,24(9):1046-1052.
|
|
[27] JUNKING M,GRAINOK J,THEPMALEE C,et al. Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA[J]. Tumour Biol,2017,39(10):1010428317733367.
|
|
[28] ARUGA A,TAKESHITA N,KOTERA Y,et al. Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer[J]. Clin Cancer Res,2013,19(8):2224-2231.
|
|
[29] ARUGA A,TAKESHITA N,KOTERA Y,et al. Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer[J]. J Transl Med,2014,12(61):61.
|
DownLoad: